How effective is filgotinib?

Filgotinib (Filgotinib) is a drug containing the active ingredient filgotinib. It is mainly used to treat two diseases in adults: moderate to severe rheumatoid arthritis and moderate to severe active ulcerative colitis. The results of multiple studies have shown that filgotinib has a significant effect in improving the symptoms of patients with moderate or severe rheumatoid arthritis, with at least 20% of symptoms relieved; in related studies on ulcerative colitis, filgotinib also showed good efficacy.

1. Moderate to severe rheumatoid arthritis

The first study involved1,755 patients whose disease was not effectively controlled while taking methotrexate. All participants continued to take methotrexate during the study and were given Jyseleca on top of that. The results showed that after a period of treatment, 77% of patients improved their symptoms; in contrast, only 71% of patients treated with adalimumab showed improvement in symptoms, and the improvement rate in the placebo group was 50%. The findings highlight the potential of Jyseleca in patients with refractory rheumatoid arthritis.

The second study evaluated 448 patients whose conditions were not adequately controlled by biologic DMARDs (drugs made from living cells). All participants continued to take regular DMARDs, with about 80% still taking methotrexate. After 12 weeks of observation, 66% of patients taking Jyseleca had improved symptoms, while the improvement rate in the placebo group was only 31%. This further validates the effectiveness of Jyseleca in the treatment of rheumatoid arthritis.

The third study focused1,249 patients who had not previously taken methotrexate but were at risk for disease progression. After 24 weeks of treatment, 81% of patients who took Jyseleca and methotrexate had improved symptoms, compared with 78% and 71% of patients who took Jyseleca and methotrexate alone, respectively. This data shows that Jyseleca can achieve better therapeutic effects when combined with traditional DMARDs.

2. Moderately to severely active ulcerative colitis

A study of patients who did or did not receive prior biologic therapy showed that afterAfter 10 weeks of treatment, 26% of patients who had not used biologics before had symptoms reduced or were completely symptom-free after using Jyseleca, while only 15% of patients in the control group achieved similar results. Among patients who had previously used biologics, 11% of those taking Jyseleca experienced mild or no symptoms, compared with 4% of those taking the placebo.

After 58 weeks of long-term follow-up observation, 37% of patients using Jyseleca showed mild symptoms or no symptoms, while only 11% of the placebo group showed symptoms. These results further demonstrate the effectiveness of filgotinib in patients with moderate or severe rheumatoid arthritis and ulcerative colitis, providing a new treatment option for these patients.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca